12 drug(s) with this reaction
28,188 total reports
Urinary Tract Infection has been reported as an adverse reaction across 12 drug(s) manufactured by Abbvie Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 28,188 adverse event reports mention urinary tract infection in connection with Abbvie Inc products.
This page provides a breakdown of which Abbvie Inc drugs are most commonly associated with urinary tract infection, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Abbvie Inc drugs have urinary tract infection listed in their FDA adverse event reports, sorted by report count:
In addition to urinary tract infection, the following adverse reactions have been reported across Abbvie Inc's drug portfolio:
12 drug(s) manufactured by Abbvie Inc have urinary tract infection listed in their FDA adverse event reports: Humira, ADALIMUMAB, LEVOTHYROXINE SODIUM, UPADACITINIB, RISANKIZUMAB-RZAA, and others.
There are a combined 28,188 reports of urinary tract infection across 12 Abbvie Inc drug(s) in the FDA adverse event database.